Arbekacin
Small moleculeexperimental
Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine. — Wikipedia
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2012 (NCT01659515)
Timeline
Indications
Mechanism of action
- 30S ribosomal protein S12INHIBITOR
rpsL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O- Mol. weight
- 552.63 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaArbekacin ↗
- ChEMBLCHEMBL426926 ↗
Also known as
- 1-n-((s)-4-amino-2-hydroxybutyryl)dibekacin
- 4-amino-2-hydroxybutylyldibekacin
- abk
- abk
- ahb-dkb
- arbekacin
- arbekacin
- arbekacin
- arbekacin
- arbekacin
- arbekacin
- arbekacin
- arbekacin
- arbekacina
- arbekacina
- arbekacine
- arbekacine
- arbekacin sulfate
- arbekacin sulfate
- arbekacin sulfate
- arbekacinum
- arbekacinum
- d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->4))-n1-((2s)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, sulfate
- haba-dkb
- habekacin
- habekacin
- habekacin
- habekacin
- haberacin
- haberacin
- o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->6))-n'-((2s)-4-amino-2-hydroxybutyryl)-2-deoxy-l-streptamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02459158 | Phase 1 | Sep 1, 2015 | Meiji Seika Pharma Co., Ltd. |
| NCT01961830 | Phase 1 | Sep 1, 2013 | Meiji Seika Pharma Co., Ltd. |
| NCT01918384 | Phase 2 | Aug 1, 2013 | Hyogo Medical University, Japan Medical Association, Kobe University, Nobel Pharmaceuticals |
| NCT01907776 | Phase 1 | Jul 1, 2013 | Meiji Seika Pharma Co., Ltd. |
| NCT01659515 | N/A | Aug 3, 2012 | Meiji Seika Pharma Co., Ltd., Uniformed Services University of the Health Sciences, United States Army |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Meiji Seika Pharma Co., Ltd. | For profit | 4 | 3 | 2 | 2012 |
| Hyogo Medical University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Japan Medical Association | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Kobe University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Nobel Pharmaceuticals | For profit | 1 | 0 | 1 | 2013 |
| Uniformed Services University of the Health Sciences | Government | 1 | 0 | 1 | 2012 |
| United States Army | Government | 1 | 1 | 1 | 2012 |
7 organizations
Page 1 / 1